SynthesisOncotarget2022
Predicting cancer immunotherapy response from gut microbiomes using machine learning models.
Synthesis in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Decoding the cancer microbiome: multi-omics, AI, and translational opportunities.Genome biology · 2026Review
- Role of gut microbiota in cancer modulation: molecular mechanisms and emerging therapeutic strategies.Infectious agents and cancer · 2026Review
- Microbial and metabolic signatures of humanized microbiome mice associate withFrontiers in immunology · 2026Article
- Exploring the Gut Microbiota as a Promising Target for Breast Cancer Treatment.Current molecular medicine · 2026Review
- Exploring Fecal Microbiota Transplantation: Potential Benefits, Associated Risks, and Challenges in Cancer Treatment.Cancer reports (Hoboken, N.J.) · 2026Review
- Emerging multifaceted roles of the microbiome in cancer susceptibility.World journal of clinical oncology · 2025Review
- Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy.Journal of clinical medicine · 2025Review
- Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer.Nature reviews. Cancer · 2025Review
- Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome.Journal of clinical medicine · 2025Review
- Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors.Cancers · 2024Review
- Metabolites in the Dance: Deciphering Gut-Microbiota-Mediated Metabolic Reprogramming of the Breast Tumor Microenvironment.Cancers · 2024Review
- Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours.Nature reviews. Cancer · 2024Review
- A review of machine learning methods for cancer characterization from microbiome data.NPJ precision oncology · 2024Review
- Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC).Cancers · 2024Review
- Microbiome bacterial influencers of host immunity and response to immunotherapy.Cell reports. Medicine · 2024Review
- GSR-DB: a manually curated and optimized taxonomical database for 16S rRNA amplicon analysis.mSystems · 2024Article
- Methodology for biomarker discovery with reproducibility in microbiome data using machine learning.BMC bioinformatics · 2024Article
- An integrated tumor, immune and microbiome atlas of colon cancer.Nature medicine · 2023Article
- The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions.Cancers · 2023Review
- The role of microbiomes in gastrointestinal cancers: new insights.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 8 institutions in 1 country.
Funding
Abstract
Cancer immunotherapy has significantly improved patient survival. Yet, half of patients do not respond to immunotherapy. Gut microbiomes have been linked to clinical responsiveness of melanoma patients on immunotherapies; however, different taxa have been associated with response status with implicated taxa inconsistent between studies. We used a tumor-agnostic approach to find common gut microbiome features of response among immunotherapy patients with different advanced stage cancers. A combined meta-analysis of 16S rRNA gene sequencing data from our mixed tumor cohort and three published immunotherapy gut microbiome datasets from different melanoma patient cohorts found certain gut bacterial taxa correlated with immunotherapy response status regardless of tumor type. Using multivariate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.